Histone Deacetylases as Targets for Melanoma Immunotherapy
Cancer represents the second leading cause of death in the United States. For many malignancies, currently available treatment options offer little long-lasting survival benefits to patients. However, recent studies have shown immunotherapeutic approaches to be an attractive strategy to cancer treat...
Main Author: | Woods, David Michael |
---|---|
Format: | Others |
Published: |
Scholar Commons
2013
|
Subjects: | |
Online Access: | http://scholarcommons.usf.edu/etd/4856 http://scholarcommons.usf.edu/cgi/viewcontent.cgi?article=6052&context=etd |
Similar Items
-
Targeting Histone Deacetylases in Melanoma and T-cells to Improve Cancer Immunotherapy
by: Sodre De Castro Laino, Andressa
Published: (2016) -
Improving histone deacetylase inhibition therapy through isoform selectivity and targeted delivery
by: Sodji, Quaovi Hemeka
Published: (2015) -
Histone deacetylases and their inhibitors: molecular mechanisms and therapeutic implications in diabetes mellitus
by: Xiaojie Wang, et al.
Published: (2012-08-01) -
Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
by: Giorgio Milazzo, et al.
Published: (2020-05-01) -
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
by: Delcuve Geneviève P, et al.
Published: (2012-03-01)